CAPA-IVM Culture With Low Oxygen Tension
1 other identifier
interventional
20
1 country
1
Brief Summary
Capacitation in-vitro maturation (CAPA-IVM) has recently been advanced in culturing oocytes from the germinal vesicle (GV) stage following mild or no controlled ovarian stimulation. Recent research suggested that O2 concentration may significantly regulate oocyte maturation and early embryo development through hypoxia-inducible factor (HIF). Nonetheless, it has been challenging to create the environmental culture conditions for addressing the optimal number of oocytes and the highest possibility of embryo development since consensus on the oxygen (O2) concentration index in the IVM culture environment has not been reached. Based on the outcomes of atmospheric O2 concentration (20%) and low O2 concentration (5%) during CAPA-IVM culture in mice, it has been hypothesized that a 5% O2 was the optimal culture condition for the pre-IVM step. A 20% O2 was more suitable for the IVM culture step. Therefore, this study is designed to enhance the CAPA-IVM culture system, improving treatment efficiency and providing various benefits for patients undergoing assisted reproductive technology.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started May 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 26, 2024
CompletedFirst Posted
Study publicly available on registry
April 16, 2024
CompletedStudy Start
First participant enrolled
May 13, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 11, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2025
CompletedJune 12, 2025
June 1, 2025
2 months
March 26, 2024
June 9, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Maturation rate
The oocyte maturation rate was usually defined by MII oocyte number divided by total COCs number
Two day after oocyte retrieval
Secondary Outcomes (46)
Total number of oocytes retrieval
On the day of oocyte retrieval
Number of patients with no oocyte retrieved
On the day of oocyte retrieval
Number of MII oocytes
Two day after oocyte retrieval
Number of GV oocytes
Two day after oocyte retrieval
Number of patients with no matured oocyte
Two day after oocyte retrieval
- +41 more secondary outcomes
Study Arms (2)
Air Oxygen Concentration CAPA-IVM culture
EXPERIMENTALHalf of the COCs will be cultured in the CAPA step and IVM step at 37 degrees Celsius in air oxygen concentration (20%) and 6% carbon dioxide.
Low Oxygen Concentration CAPA-IVM culture
ACTIVE COMPARATORHalf of the COCs will be cultured in the CAPA step at a low oxygen concentration (5%) and IVM step at an air oxygen concentration (20%); all two steps combine 6% carbon dioxide at 37 degrees Celsius.
Interventions
* Group 1A: COC will be cultured in the CAPA step at an air oxygen concentration (20%) for 24 hours and 6% carbon dioxide at 37 degrees Celsius. * Group 1B: COCs will be cultured in the CAPA step at an air oxygen concentration (20%) for 24 hours and in the IVM step at an air oxygen concentration (20%) for 30 hours; all two steps combine 6% carbon dioxide at 37 degrees Celsius.
* Group 2A: COC will be cultured in the CAPA step at a low oxygen concentration (5%) for 24 hours and 6% carbon dioxide at 37 degrees Celsius. * Group 2B: COCs will be cultured in the CAPA step at a low oxygen concentration (5%) for 24 hours and the IVM step at an air oxygen concentration (20%) for 30 hours; all two steps combine 6% carbon dioxide at 37 degrees Celsius.
Eligibility Criteria
You may qualify if:
- years of age
- Diagnosed with polycystic ovary syndrome according to the Rotterdam criteria (2003)
- Indicating CAPA-IVM treatment
- Having at least 40 antral follicles in two ovaries by transvaginal ultrasound at the time of CAPA-IVM indication
- Agreeing to have frozen embryo transfer
- Agreeing to participate in the trial
You may not qualify if:
- Cycles with oocyte donation, preimplantation Genetic Testing (PGT)
- Couples with severe male factor (sperm concentration \<5 million/ml, motility \< 10%), surgical sperm retrieval
- Previous history of unexplained immature oocytes after IVF treatment
- Uterine abnormalities
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mỹ Đức Hospitallead
- Vrije Universiteit Brusselcollaborator
Study Sites (1)
My Duc Hospital
Ho Chi Minh City, Vietnam
Related Publications (11)
Practice Committees of the American Society for Reproductive Medicine, the Society of Reproductive Biologists and Technologists, and the Society for Assisted Reproductive Technology. Electronic address: jgoldstein@asrm.org. In vitro maturation: a committee opinion. Fertil Steril. 2021 Feb;115(2):298-304. doi: 10.1016/j.fertnstert.2020.11.018. Epub 2020 Dec 24.
PMID: 33358333BACKGROUNDPaulson RJ, Fauser BCJM, Vuong LTN, Doody K. Can we modify assisted reproductive technology practice to broaden reproductive care access? Fertil Steril. 2016 May;105(5):1138-1143. doi: 10.1016/j.fertnstert.2016.03.013. Epub 2016 Apr 4.
PMID: 27054309BACKGROUNDVuong LN, Ho VNA, Ho TM, Dang VQ, Phung TH, Giang NH, Le AH, Pham TD, Wang R, Smitz J, Gilchrist RB, Norman RJ, Mol BW. In-vitro maturation of oocytes versus conventional IVF in women with infertility and a high antral follicle count: a randomized non-inferiority controlled trial. Hum Reprod. 2020 Nov 1;35(11):2537-2547. doi: 10.1093/humrep/deaa240.
PMID: 32974672BACKGROUNDGilchrist RB, Ho TM, De Vos M, Sanchez F, Romero S, Ledger WL, Anckaert E, Vuong LN, Smitz J. A fresh start for IVM: capacitating the oocyte for development using pre-IVM. Hum Reprod Update. 2024 Jan 3;30(1):3-25. doi: 10.1093/humupd/dmad023.
PMID: 37639630BACKGROUNDZhao X, Liu X, Feng Y, Shi D, Lu F. Regulation of hypoxia-inducible factor 1alpha by optimal oxygen concentration enhances oocyte maturation and early embryonic development in buffalo. Theriogenology. 2023 Aug;206:50-59. doi: 10.1016/j.theriogenology.2023.05.006. Epub 2023 May 8.
PMID: 37187055BACKGROUNDFischer B, Bavister BD. Oxygen tension in the oviduct and uterus of rhesus monkeys, hamsters and rabbits. J Reprod Fertil. 1993 Nov;99(2):673-9. doi: 10.1530/jrf.0.0990673.
PMID: 8107053BACKGROUNDBahrami M, Cottee PA. Culture conditions for in vitro maturation of oocytes - A review. Reproduction and Breeding. 2022 Jun 1;2(2):31-6
BACKGROUNDIncreased susceptibility to oxidative stress as a proximate cost of reproduction - Alonso-Alvarez - 2004 - Ecology Letters - Wiley Online Library [Internet]. [cited 2023 Sep 19]. Available from: https://onlinelibrary.wiley.com/doi/10.1111/j.1461-0248.2004.00594.x
BACKGROUNDAkin N, Ates G, von Mengden L, Herta AC, Meriggioli C, Billooye K, Stocker WA, Ghesquiere B, Harrison CA, Cools W, Klamt F, Massie A, Smitz J, Anckaert E. Effects of lactate, super-GDF9, and low oxygen tension during bi-phasic in vitro maturation on the bioenergetic profiles of mouse cumulus-oocyte complexdagger. Biol Reprod. 2023 Oct 13;109(4):432-449. doi: 10.1093/biolre/ioad085.
PMID: 37531262BACKGROUNDHerta AC, von Mengden L, Akin N, Billooye K, Coucke W, van Leersum J, Cava-Cami B, Saucedo-Cuevas L, Klamt F, Smitz J, Anckaert E. Characterization of carbohydrate metabolism in in vivo- and in vitro-grown and matured mouse antral folliclesdagger. Biol Reprod. 2022 Oct 11;107(4):998-1013. doi: 10.1093/biolre/ioac124.
PMID: 35717588BACKGROUNDRotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004 Jan;19(1):41-7. doi: 10.1093/humrep/deh098.
PMID: 14688154BACKGROUND
Study Officials
- PRINCIPAL INVESTIGATOR
Lan N Vuong, MD, PhD
University of Medicine and Pharmacy at Ho Chi Minh City
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 26, 2024
First Posted
April 16, 2024
Study Start
May 13, 2024
Primary Completion
July 11, 2024
Study Completion
June 1, 2025
Last Updated
June 12, 2025
Record last verified: 2025-06